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Abstract Aims/hypothesis: The IL-1 receptor antagonist
(IL-1Ra) is an anti-inflammatory cytokine known to antag-
onise the actions of IL-1. We have previously shown that
IL-1Ra is markedly upregulated in the serum of obese
patients, is correlated with BMI and insulin resistance, and
is overexpressed in the white adipose tissue (WAT) of obese
humans. The aim of this study was to examine the role of
IL-1Ra in the regulation of glucose homeostasis in rodents.
Methods: We assessed the expression of genes related to
IL-1 signalling in the WAT of mice fed a high-fat diet, as
well as the effect of Il1rn (the gene for IL-1Ra) deletion and
treatment with IL-1Ra on glucose homeostasis in rodents.
Results: We show that the expression of Il1rn and the gene
encoding the inhibitory type II IL-1 receptor was upregu-
lated in diet-induced obesity. The blood insulin:glucose
ratio was significantly lower in Il1rn−/−animals, which is
compatible with an increased sensitivity to insulin,
reinforced by the fact that the insulin content and pancreatic
islet morphology of Il1rn−/− animals were normal. In con-
trast, the administration of IL-1Ra to normal rats for 5 days
led to a decrease in the whole-body glucose disposal due to
a selective decrease in muscle-specific glucose uptake.
Conclusions/interpretation: The expression of genes en-
coding inhibitors of IL-1 signalling is upregulated in the
WATof mice with diet-induced obesity, and IL-1Ra reduces
insulin sensitivity in rats through a muscle-specific de-
crease in glucose uptake. These results suggest that the
markedly increased levels of IL-1Ra in human obesity
might contribute to the development of insulin resistance.
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Abbreviations IL-1Ra: IL-1 receptor antagonist . IL-1RI:
IL-1 receptor type I . IL-1RII: IL-1 receptor type II .
Ra: rate of glucose appearance . Rd: rate of glucose
disappearance . rhIL-1Ra: recombinant human IL-1
receptor antagonist . WAT: white adipose tissue .
WATe: epididymal WAT
Introduction
Adipose tissue is an important source of cytokines and
related peptides, regulating body weight homeostasis and
insulin sensitivity. Increased production of TNF-α has been
detected in the white adipose tissue (WAT) of different
rodent models of genetic obesity and it has been speculated
that TNF-α contributes to the development of insulin re-
sistance [1]. Clinical studies have also demonstrated the
overexpression of Tnf mRNA in different WAT depots of
obese humans, as well as a positive correlation between Tnf
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expression and hyperinsulinaemia [2, 3], in spite of normal
circulating serum TNF-α levels [4, 5]. IL-6 has also been
shown to be produced by human omental and subcutaneous
adipose tissue [6, 7], with serum levels positively correlated
with BMI [8]. However, although serum levels of IL-6 are
slightly elevated in obese patients [9, 10], they are not
increased beyond the upper limit of the physiological range.
We have recently demonstrated that levels of IL-1 receptor
antagonist (IL-1Ra) are nearly seven times higher in sera
from obese humans [11] and that WAT contributes to the
production of this cytokine [12]. We have also shown that
this cytokine is overexpressed in the WAT of leptin-de-
ficient ob/ob mice, as it is in the subcutaneous adipose
tissue of obese patients [12].
IL-1Ra antagonises the two proinflammatory cytokines
IL-1α and IL-1β by inhibiting their binding to the func-
tional type I IL-1 receptor (IL-1RI) [13]. The type II IL-1
receptor (IL-1RII) acts as a decoy receptor, inhibiting IL-1
signalling [14]. To date, the relationship between obesity
and the molecules related to IL-1 signalling has not been
examined. Moreover, while the anti-inflammatory role of
IL-1Ra is well established, the metabolic relevance of in-
creased serum levels of IL-1Ra observed in human obesity
remains speculative, although several lines of evidence
suggest that IL-1Ra favours obesity by antagonising the
anorexic [11, 15], anti-adipogenic [16, 17] and insulin-
sensitising effects of IL-1 [18]. Therefore, the aim of this
study was to examine the effect of diet-induced obesity in
mice on the expression of the genes for various components
of the IL-1 signalling pathway in WAT, such as IL-1Ra,
IL-1β, IL-1RI and IL-1RII. Since IL-1Ra serum levels in
humans are more strongly correlated with insulin resistance
than BMI [11], we also assessed the role of IL-1Ra as a
regulator of insulin sensitivity by using Il1rn (formerly
known as IL-1ra) knockout mice and by administrating
IL-1Ra to normal rats.
Materials and methods
Animals All experimental protocols were approved by the
Cantonal Veterinary Office (Geneva, Switzerland). Ten-
week-old C57BL/6J male mice, weighing approximately
25 g, were obtained from the Janvier Breeding Centre (Le
Genest-Saint-Isle, France) and housed at room temperature
(22°C), with a 12-h light–dark cycle and free access to
water and food. After 2 weeks of acclimatisation, mice were
housed individually and provided with either a standard
chow diet (6.6% of energy from fat, 76.8% from carbohy-
drate and 16.6% from protein) or a high-fat diet (39.8% of
energy from fat, 43.6% from carbohydrate and 16.6% from
protein). The composition of these diets is given in Table 1.
Animals were killed after receiving standard chow or the
high-fat diet for 35 weeks. Epididymal white adipose tissue
(WATe) was removed and immediately frozen in liquid
nitrogen for RNA preparation.
The generation of the Ilrn knockout mice by homologous
recombination has been described previously [19]. These
mice were backcrossed to the C57BL/6J strain mice for
more than ten generations and can be regarded as genet-
ically homogeneous. Mice were housed individually from
weaning, kept under specific pathogen-free conditions in an
environmentally controlled clean room at the University
Medical Centre (University of Geneva), and were allowed
free access to standard chow diet. These mice were killed at
36–45 weeks of age, in the morning, 3 h after food removal.
After killing, blood was collected in EDTA-coated tubes,
placed on ice, centrifuged, and plasma was frozen. Plasma
glucose was subsequently measured by the glucose oxidase
method, and plasma insulin was assessed using a previously
validated RIA [20].
For the clamp studies, 12-week-old OFA-SD wild-type
male rats, weighing approximately 450 g, were obtained
from Charles River Laboratories (St Germain-sur-l’Arbresle,
France) and housed individually at room temperature
(22°C), with a 12-h light–dark cycle and free access to
water and food, before undergoing treatment with recom-
binant human IL-1Ra (rhIL-1Ra) (Kineret; Amgen Europe,
Minervum, the Netherlands) and euglycaemic–hyperinsulin-
aemic clamps, as described below. Body weight and food
intake, measured daily during the baseline period and rhIL-
1Ra treatment, are given in Table 2.
RNA preparation and mRNA quantification Total RNA
was prepared from 200 mg of WATe using the Trizol
reagent (Invitrogen, Basel, Switzerland) according to the
manufacturer’s instructions. Total RNA (5 μg) was reverse-
transcribed using 800 U Moloney murine leukaemia virus
reverse transcriptase (Invitrogen) in the presence of RNA
sin (0.3 U/μl) (Promega Corp., Madison, WI, USA), ran-
dom primers (oligo[dN]6, 7.5 μmol/l), dNTP (1.2 mmol/l)
and dithiothreitol (12 μmol/l). Levels of transcripts of the
genes encoding IL-1Ra (Il1rn), IL-1β (Il1b), IL-1RI (Il1r1),
IL-1RII (Il1r2), TNF-α (Tnf), IL-6 (Il6), and of Arbp, a
housekeeping gene, in the mouse were determined by quan-
titative real-time PCR using a LightCycler (Roche Diag-
nostics, Rotkreuz, Switzerland) with the DNA Master
SYBR Green I or Fast Start DNA Master SYBR Green I
(Roche Molecular Biochemicals, Rotkreuz, Switzerland)
kits as appropriate [12]. Levels of each of the mRNAs were
quantified in at least two independent LightCycler runs for
each individual sample. The sequences of the primers used
are shown in Table 3.
Measurement of insulin content of pancreas For measure-
ment of insulin content, the whole pancreas was extracted
in acid–ethanol before RIA, as previously described [20].
Table 1 Diet composition
Standard chow diet High-fat diet
Crude protein (N × 6.25) (g/kg) 180 180
Crude fibre (g/kg) 53 35
Crude fat (g/kg) 26 200
Ash (g/kg) 59 35
Nitrogen-free extract (g/kg) 615 470
Metabolisable energy (MJ/kg) 10.9 18.0
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Histological examination of pancreas and immunohisto-
logical determination of insulin The pancreases of four
mice per genotype were fixed in Bouin’s solution, embed-
ded in paraffin, and sections were stained with haematox-
ylin/eosin or processed for immunolabelling of insulin, as
previously reported [21].
Euglycaemic–hyperinsulinaemic clamps Rats were treated
for 5 days with either vehicle (154 mmol NaCl/l) or rhIL-
1Ra (s.c. injections of rhIL-1Ra two times per day, 6 mg/
kg), with the last injection given 1 h before the start of the
experiment. Before the euglycaemic–hyperinsulinaemic
clamp studies, the rats were fasted for 15 h and anaes-
thetised with i.p. sodium pentobarbital (55 mg/kg). The
clamps were performed using a constant infusion of 3 mU
insulin (Actrapid, Novo Nordisk, Bagsvaerd, Denmark) per
min, and the glucose infusion rate needed to maintain
normoglycaemia was determined. To measure total glucose
utilisation (rate of glucose disappearance [Rd]) and hepatic
glucose production (rate of glucose appearance [Ra]),
euglycaemic–hyperinsulinaemic clamps were performed
with an infusion of D-[U-14C]glucose (1.850 MBq per rat;
Amersham, Aylesbury, UK), according to the method pre-
viously described [22]. At the end of the experiment, a
bolus of 2-deoxy-D-[1-3H]glucose (1.110 MBq per rat;
Amersham) was injected intravenously to measure the in
vivo insulin-stimulated glucose utilisation indices of spe-
cific tissues (muscle and adipose tissue), as previously
described [23, 24]. The tibialis muscle and WATe were
frozen for further analysis.
Analytical procedures relative to clamp studies The spe-
cific activities of 2-deoxy-D-[1-3H]glucose and D-[U-14C]
glucose were determined in deproteinised blood samples, as
previously reported [23, 24]. Measurement of the tissue
concentration of 2-deoxy-D-[1-3H]glucose 6-phosphate al-
lowed calculation of the in vivo glucose utilisation index in
individual tissues and was expressed as mg min−1 kg−1
tissue [23, 24]. Plasma glucose was measured by the glu-
cose oxidase method (Glucose Analyzer 2; Beckman
Coulter, Fullerton, CA, USA), and plasma insulin was
quantified using a previously described RIA [25].
Statistical analysis Results are expressed as means ±
SEM. The unpaired Student’s t test was used for com-
parison between groups of mice used in the high-fat diet
experiments (n=9 animals in each group), for comparison
between Il1rn−/− and wild-type mice used for glucose and
insulin measurements (n=3–6 animals in each group), and
for comparison between groups of rats used in the clamp
experiments (n=7–8 animals in each group). These tests
and linear regressions were performed with SYSTAT,
version 10.01 software (SPSS, Chicago, IL, USA). A p
value of less than 0.05 was considered statistically
significant.
Results
Effect of a high-fat diet on expression in the WAT of genes
encoding proteins involved in the IL-1 signalling pathway
Mice provided with a high-fat diet for 35 weeks had a
higher body weight (44.4±1.0 g) than age-matched controls
Table 2 Physiological and metabolic parameters of rhIL-1Ra-treated and control rats, before and during euglycaemic–hyperinsulinaemic
clamps
Body weight
(g)
Food intake
(g/day)
Glycaemia basal
(mmol/l)
Glycaemia after clamp
(mmol/l)
Insulinaemia basal
(ng/ml)
Insulinaemia after clamp
(ng/ml)
Control 463±8.3 28±0.7 5.9±0.4 7.6±0.1 1.8±0.2 8.5±0.6
rhIL-1Ra-
treated
445±9.7 28±2.0 6.5±0.2 7.4±0.1 1.6±0.1 7.2±0.5
Student’s
t test
NS NS NS NS NS NS
Values are means ± SEM for seven to eight animals per group
rhIL-1Ra-rats were treated for 5 days with two daily s.c. injections of rhIL-1Ra (6 mg/kg); controls were injected s.c. with saline
(154 mmol NaCl/l)
Table 3 Primer sequences used for real-time RT-PCR
Gene targeted Sense Antisense
Il1rn 5′-AAATCTGCTGGGGACCCTAC-3′ 5′-TCTTCTAGTTTGATATTTGGTCCTTG-3′
Il1b 5′-TGTGAAATGCCACCTTTTGA-3′ 5′-GTGCTCATGTCCTCATCCTG-3′
Il1r1 5′-GAATGACCCTGGCTTGTGTT-3′ 5′-TGTGCTCTTCAGCCACATTC-3′
Il1r2 5′-GAGGGGCTACACCACCAGTA-3′ 5′-GGATTCGAGGCAACACATTT-3′
Tnf 5′-AGTTCTATGGCCCAGACCCT-3′ 5′-GTCTTTGAGATCCATGCCGT-3′
Il6 5′-CACTTCACAAGTCGGAGCT-3′ 5′-TTCTGCAAGTGCATCATCG-3′
Arbp 5′-CTGAACATCTCCCCCTCTC-3′ 5′-CGAATCCCATATCCTCATC-3′
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fed a standard chow diet (35.2±0.8 g). No significant var-
iation was found in glycaemia and insulinaemia between
the two groups of animals (results not shown). Using quan-
titative RT-PCR, we examined the expression of the genes
encoding the different components of the IL-1 signalling
system in the adipose tissue of mice fed on the standard
chow or the high-fat diet. As shown in Fig. 1a, the expres-
sion of genes encoding inhibitors of the IL-1 signalling
pathway (IL-1Ra and IL-1RII) was upregulated in the
WATe of mice with diet-induced obesity (fold increase:
6.4±1.2 and 3.0±0.3 for Il1rn and Il1r2 mRNA, respec-
tively, p<0.01). In contrast, no significant change in the
expression of genes for activators of the IL-1 signalling
pathway (IL-1β and IL-1RI) was detected between the
WATe of obese and lean animals. For comparison, we
analysed the expression of genes encoding TNF-α and IL-
6, previously shown to be expressed in adipose tissue.
Indeed, when compared with those in lean mice, Tnf
mRNA levels were increased by a factor of 2.0±0.4
(p<0.02) in the WATe of obese mice, while Il6 mRNA
levels were not significantly altered (Fig. 1a). Interestingly,
the expression of Il1rn in WATe was strongly correlated
with body weight (r2=0.56, p<0.0001) (Fig. 1b), as was the
expression of Il1r2 (r2=0.68, p<0.0001) (Fig. 1c), while no
correlations with Tnf or Il6 mRNAwere found (results not
shown).
Effect of Il1rn deletion (Il1rn−/−) on circulating levels of
glucose and insulin To study the role of endogenous Il1rn
in glucose homeostasis, we investigated serum glucose and
insulin levels in Il1rn-deficient mice. Il1rn−/−mice had a
reduced body weight compared with wild-type animals
(22.4±1.1 vs 33.0±0.3 g, respectively), as has been previ-
ously reported [18]. Postprandial glycaemia and insulin-
aemia (measured after 3 h of food deprivation) were 28±9%
(p<0.05) and 53±5% (p<0.002) lower in Il1rn−/−mice than
in wild-type mice, respectively (Fig. 2a,b). Hence, the
insulin:glucose ratio was 31±6% lower in Il1rn−/− mice
than in wild-type mice (p<0.005) (Fig. 2c), which is com-
patible with the increased insulin sensitivity in this group of
animals.
Effect of Il1rn deletion on pancreatic insulin content and
islet morphology To determine if reduced insulin levels in
Il1rn-deficient mice were the result of a developmental beta
cell defect, we measured insulin production by the pan-
creas. Although pancreatic weight normalised to body weight
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after a high-fat diet and levels are correlated with body weight in
mice. a Il1rn, Il1b, Il1r1, Il1r2, Tnf and Il6 mRNA levels in WATe
isolated from mice fed a standard chow (open bars) or a high-fat
(black bars) diet for 35 weeks. All mRNAs were quantified by real-
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for nine animals (*p<0.05 for comparison between standard chow
and high-fat diet). b Correlation between Il1rn mRNA expression in
WATe and body weight in mice after consumption of a standard
chow or a high-fat diet for 35 weeks (linear regression analysis:
r2=0.56, p<0.0001, n=18 animals). c Correlation between Il1r2
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Fig. 2 Il1rn deletion (Il1rn−/−)
decreases serum glucose and
insulin levels in mice. a Glucose
levels in wild-type (open bar),
Il1rn+/− (grey bar) and Il1rn−/−
(black bar) mice in the post-
prandial state, 3 h after food
removal (*p<0.05 vs wild-type
mice). b Insulin levels in the
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was 9±4% lower in Il1rn−/− mice than in wild-type mice
(p<0.05) (Fig. 3a), the pancreatic insulin content was un-
changed in Il1rn−/−mice compared with either heterozygous
or wild-type mice (Fig. 3b). Moreover, histological (Fig. 3c)
and immunohistological (Fig. 3d) analysis of the pancreas
revealed that the pancreatic islets of Il1rn−/− mice were
similar to those of wild-type mice in terms of morphology,
size and insulin store.
Effect of IL-1Ra on glucose homeostasis Following our
previous observation that circulating IL-1Ra levels are
chronically and markedly elevated in obese patients [11], in
the present study we assessed the effects of prolonged IL-
1Ra excess on glucose homeostasis and insulin sensitivity
in rodents. We injected rats s.c. twice daily for 5 days with
either saline (154 mmol NaCl/l) or rhIL-1Ra (6 mg/kg). No
significant difference in body weight or food intake was
observed between rhIL-1Ra-treated and control rats (Table 2).
Basal glycaemia and basal insulinaemia were also similar in
control rats and animals injected with rhIL-1Ra. However,
the glucose infusion rate needed to maintain stable gly-
caemia during the euglycaemic–hyperinsulinaemic clamps
was significantly decreased (by 24±4%, p<0.05) in animals
treated with rhIL-1Ra, while the glycaemia after the clamps
was similar in both groups (Table 2 and Fig. 4a). Eugly-
caemic–hyperinsulinaemic clamps were then performed
with [14C]glucose to determine Rd and Ra. Compared
with control animals, basal Rd was decreased (p<0.05) by
21±8% in rhIL-1Ra-treated rats (Fig. 4b). Similarly, in-
sulin-stimulated Rd was 32±8% lower (p<0.05) in the
treated group than in the control group (Fig. 4b). During the
clamps, Ra was similarly suppressed by insulin in both
groups (results not shown).
Taken together, these results indicate that excess IL-1Ra
reduced the sensitivity of peripheral tissues to insulin.
Effect of IL-1Ra on tissue-specific glucose utilisation Tis-
sue-specific glucose utilisation was measured by the la-
belled 2-deoxy-D-[1-3H]glucose technique at the end of
euglycaemic–hyperinsulinaemic clamps. Insulin-stimulat-
ed glucose utilisation by the tibialis muscle (Fig. 4c) was
decreased by 36±4% (p<0.05) in rats treated with rhIL-1Ra
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compared with that in controls. A trend towards a decrease
in utilisation was also observed in the quadriceps and
gastrocnemius muscles (results not shown). In contrast, in-
sulin-stimulated glucose utilisation was unchanged in WATe
(Fig. 4d) and in the inguinal and perirenal WAT depots
(results not shown). Hence, these results demonstrate a
muscle-specific decrease in insulin sensitivity of rats treated
with rhIL-1Ra.
Discussion
In this study we have shown that diet-induced obesity en-
hances the expression of Il1rn in mouse WAT. This
observation is in line with our previous finding of a nearly
40-fold increase in levels of Il1rnmRNA in the WATof ob/
obmice with long-standing severe obesity [12] and a seven-
fold increase in serum levels of IL-1Ra in obese humans
[11]. Interestingly, the increase in Il1rn mRNA observed in
WAT during diet-induced obesity is associated with a three-
fold increase in Il1r2 mRNA. This suggests that IL-1 sig-
nalling is downregulated in obesity, not only systemically,
but also locally in WAT. Since IL-1 is known to enhance
insulin action under certain conditions [26, 27], it is pos-
sible that the decreased signalling of IL-1 contributes to
obesity-associated insulin resistance. As previously report-
ed [1], we confirmed the increased expression of Tnf in the
WAT from mice with diet-induced obesity, while no alter-
ation of Il6 expression was found. This is in contrast to the
previously reported overexpression of Il6 in the WAT of
genetically obese ob/ob mice [28], which, however, have a
much more pronounced increase in fat mass than our model
of diet-induced obesity.
Since we reported in our earlier human studies that IL-
1Ra serum levels are better correlated with insulin sensi-
tivity than with BMI [11], we used rodent models of IL-1Ra
deficiency and excess to examine a possible causal relation-
ship among IL-1, IL-1Ra and glucose homeostasis. Il1rn−/−
mice showed a decrease in serum insulin levels, as well as a
decreased insulin:glucose ratio, supporting the enhanced
insulin sensitivity previously reported in these animals [18].
However, since IL-1 was previously shown to be toxic to
islets [29, 30], we examined whether there was any alter-
ation in pancreatic insulin content and/or islet structure in
Il1rn knockout mice. Since no obvious pancreatic or islet
anomaly was found, it is likely that the normoglycaemic–
hypoinsulinaemic status of the knockout animals reflects an
increase in peripheral insulin sensitivity, as a result of a
chronic unopposed IL-1 action.
The hypothesis that IL-1Ra is an insulin-desensitising
factor was substantiated by the treatment of normal rats
with rhIL-1Ra, which resulted in a decreased rate of glucose
utilisation in both the basal and insulin-stimulated state
during euglycaemic–hyperinsulinaemic clamps. The insu-
lin resistance of rhIL-1Ra-treated rats was unrelated to he-
patic glucose production, which was normally suppressed
by insulin in both the controls and the rhIL-1Ra-treated
animals. The finding that IL-1Ra leads to insulin resistance
in rats is in keeping with our earlier clinical observation that
serum IL-1Ra levels are positively correlated with insulin
resistance in obese humans (r2=0.58) [11]. Interestingly, the
glucose utilisation index of insulin-sensitive tissues was
selectively decreased in the skeletal muscle of rhIL-1Ra-
treated rats. The reason for this tissue-specific effect re-
mains to be elucidated. However, the observed reduction in
global Rd is well explained by the reduction in 2-deoxy-D-
[1-3H]glucose uptake into muscle cells. These observations
are in agreement with previous pharmacological studies
demonstrating that the chronic administration of IL-1 to
rodents induces hypoglycaemia, probably due to increased
glucose transport into tissues to increase the energy sup-
ply to tissues during high metabolic demands [31–33]. Fur-
ther investigations are required to understand the crosstalk
between IL-1 and insulin signalling at the cellular and
molecular level, and to determine whether phosphatidyl-
inositol-3-kinase, which participates in IL-1 and insulin
signalling, is implicated. While the principal aim of this
study was to examine the metabolic impact of excess IL-
1Ra as it is observed in human obesity, clamp studies in IL-
1Ra-deficient mice would be useful to validate these findings.
In conclusion, we have shown that the expressions of
Il1rn and Il1r2, the decoy receptor, are strongly upregulated
in WATe after high-fat feeding, and the extent of upreg-
ulation is proportional to body weight. Moreover, excess
IL-1Ra leads to impaired glucose uptake in skeletal muscle.
These results support the hypothesis that IL-1Ra provides a
functional link between obesity and insulin resistance.
Acknowledgements This work was supported by Swiss National
Science Foundation (SNSF) Grants 3200B0-103618 to C. A. Meier
and 3100A0-105889/1 to F. Rohner-Jeanrenaud. The work of P.
Meda was supported by grants from the SNSF (310000-109402), the
JDRF (1-2005-46), the EU (QLRT-2001-01777) and the NIH (RO1
DK-63443). This study was part of the Geneva programme for
metabolic disorders (GeMet). The authors confirm the absence of any
conflict of interest.
References
1. Hotamisligil GS, Shargill NS, Spiegelman BM (1993) Adipose
expression of tumor necrosis factor-alpha: direct role in obesity-
linked insulin resistance. Science 259:87–91
2. Hotamisligil GS, Arner P, Caro JF et al (1995) Increased
adipose tissue expression of tumor necrosis factor-alpha in
human obesity and insulin resistance. J Clin Invest 95:2409–
2415
3. Kern PA, Saghizadeh M, Ong JM et al (1995) The expression
of tumor necrosis factor in human adipose tissue. Regulation by
obesity, weight loss, and relationship to lipoprotein lipase. J
Clin Invest 95:2111–2119
4. Pincelli AI, Brunani A, Scacchi M et al (2001) The serum
concentration of tumor necrosis factor alpha is not an index of
growth-hormone- or obesity-induced insulin resistance. Horm
Res 55:57–64
5. Ronnemaa T, Pulkki K, Kaprio J (2000) Serum soluble tumor
necrosis factor-alpha receptor 2 is elevated in obesity but is not
related to insulin sensitivity: a study in identical twins
discordant for obesity. J Clin Endocrinol Metab 85:2728–2732
6. Mohamed-Ali V, Goodrick S, Rawesh A et al (1997) Subcuta-
neous adipose tissue releases interleukin-6, but not tumor
necrosis factor-alpha, in vivo. J Clin Endocrinol Metab 82:
4196–4200
392
7. Fried SK, Bunkin DA, Greenberg AS (1998) Omental and
subcutaneous adipose tissues of obese subjects release inter-
leukin-6: depot difference and regulation by glucocorticoid. J
Clin Endocrinol Metab 83:847–850
8. Vgontzas AN, Papanicolaou DA, Bixler EO et al (1997)
Elevation of plasma cytokines in disorders of excessive daytime
sleepiness: role of sleep disturbance and obesity. J Clin
Endocrinol Metab 82:1313–1316
9. Roytblat L, Rachinsky M, Fisher A et al (2000) Raised
interleukin-6 levels in obese patients. Obes Res 8:673–675
10. Bastard JP, Jardel C, Bruckert E et al (2000) Elevated levels of
interleukin 6 are reduced in serum and subcutaneous adipose
tissue of obese women after weight loss. J Clin Endocrinol
Metab 85:3338–3342
11. Meier CA, Bobbioni E, Gabay C et al (2002) IL-1 receptor
antagonist serum levels are increased in human obesity: a
possible link to the resistance to leptin? J Clin Endocrinol
Metab 87:1184–1188
12. Juge-Aubry CE, Somm E, Giusti V et al (2003) Adipose tissue
is a major source of interleukin-1 receptor antagonist: upreg-
ulation in obesity and inflammation. Diabetes 52:1104–1110
13. Arend WP (1990) Interleukin-1 receptor antagonist: discovery,
structure and properties. Prog Growth Factor Res 2:193–205
14. Neumann D, Kollewe C, Martin MU et al (2000) The
membrane form of the type II IL-1 receptor accounts for
inhibitory function. J Immunol 165:3350–3357
15. Luheshi GN, Gardner JD, Rushforth DA et al (1999) Leptin
actions on food intake and body temperature are mediated by
IL-1. Proc Natl Acad Sci USA 96:7047–7052
16. Gregoire F, De Broux N, Hauser N et al (1992) Interferon-
gamma and interleukin-1 beta inhibit adipoconversion in
cultured rodent preadipocytes. J Cell Physiol 151:300–309
17. Suzawa M, Takada I, Yanagisawa J et al (2003) Cytokines
suppress adipogenesis and PPAR-gamma function through the
TAK1/TAB1/NIK cascade. Nat Cell Biol 5:224–230
18. Matsuki T, Horai R, Sudo K et al (2003) IL-1 plays an
important role in lipid metabolism by regulating insulin levels
under physiological conditions. J Exp Med 198:877–888
19. Nicklin MJ, Hughes DE, Barton JL et al (2000) Arterial
inflammation in mice lacking the interleukin 1 receptor antag-
onist gene. J Exp Med 191:303–312
20. Meda P, Bosco D, Chanson M et al (1990) Rapid and reversible
secretion changes during uncoupling of rat insulin-producing
cells. J Clin Invest 86:759–768
21. Charollais A, Gjinovci A, Huarte J et al (2000) Junctional
communication of pancreatic beta cells contributes to the
control of insulin secretion and glucose tolerance. J Clin Invest
106:235–243
22. Terrettaz J, Assimacopoulos-Jeannet F, Jeanrenaud B (1986)
Severe hepatic and peripheral insulin resistance as evidenced by
euglycemic clamps in genetically obese fa/fa rats. Endocrinol-
ogy 118:674–678
23. Cusin I, Terrettaz J, Rohner-Jeanrenaud F et al (1990)
Metabolic consequences of hyperinsulinaemia imposed on
normal rats on glucose handling by white adipose tissue,
muscles and liver. Biochem J 267:99–103
24. Vettor R, Zarjevski N, Cusin I et al (1994) Induction and
reversibility of an obesity syndrome by intracerebroventricular
neuropeptide Y administration to normal rats. Diabetologia
37:1202–1208
25. Herbert V, Lau KS, Gottlieb CW et al (1965) Coated charcoal
immunoassay of insulin. J Clin Endocrinol Metab 25:1375–
1384
26. Del Rey A, Besedovsky H (1987) Interleukin 1 affects glucose
homeostasis. Am J Physiol 253:R794–R798
27. Del Rey A, Monge-Arditi G, Besedovsky HO (1998) Central
and peripheral mechanisms contribute to the hypoglycemia
induced by interleukin-1. Ann N Y Acad Sci 840:153–161
28. Harkins JM, Moustaid-Moussa N, Chung YJ et al (2004)
Expression of interleukin-6 is greater in preadipocytes than in
adipocytes of 3T3-L1 cells and C57BL/6J and ob/ob mice. J
Nutr 134:2673–2677
29. Maedler K, Sergeev P, Ris F et al (2002) Glucose-induced beta
cell production of IL-1beta contributes to glucotoxicity in
human pancreatic islets. J Clin Invest 110:851–860
30. Jhala U, Baly DL (1994) Effect of chronic IL-1 beta infusion on
glucose homeostasis and pancreatic insulin secretion. Life Sci
54:413–422
31. Besedovsky HO, del Rey A (1989) Interleukin-1 and glucose
homeostasis: an example of the biological relevance of
immune-neuroendocrine interactions. Horm Res 31:94–99
32. Del Rey A, Besedovsky H (1989) Antidiabetic effects of
interleukin 1. Proc Natl Acad Sci USA 86:5943–5947
33. Lang CH, Dobrescu C (1989) Interleukin-1 induced increases
in glucose utilization are insulin mediated. Life Sci 45:2127–
2134
393
